Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study
Status In-Process Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu dopisy
Grantová podpora
Not applicable
Amgen (Amgen Inc.)
PubMed
41233549
PubMed Central
PMC12789001
DOI
10.1038/s41375-025-02800-6
PII: 10.1038/s41375-025-02800-6
Knihovny.cz E-zdroje
Amgen Inc Thousand Oaks CA USA
Amgen Research GmbH Munich Germany
Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon Napoli Italy
Catholic University of the Sacred Heart Rome Italy
Charité Universitaetsmedizin CVK Berlin Berlin Germany
Charles University Prague University Hospital Prague Czech Republic
Department of Pediatrics Jena University Hospital Jena Germany
Hopital Armand Trousseau APHP Sorbonne Université Paris France
IRCCS Istituto Giannina Gaslini Genova Italy
IRCCS Ospedale Pediatrico Bambino Gesù Rome Italy
Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico G Gaslini Genova Italy
Medizinische Hochschule Hannover Hannover Germany
Pediatric Hematology Oncology Unit IRCCS Foundation San Gerardo dei Tintori Monza Italy
St Anna Children's Hospital Children's Cancer Research Institute Vienna Austria
Tata Translational Cancer Research Centre Tata Medical Center Kolkata India
Universitätsklinikum Freiburg Freiburg Germany
Zobrazit více v PubMed
Eckert C, Parker C, Moorman AV, Irving JA, Kirschner-Schwabe R, Groeneveld-Krentz S, et al. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer. 2021;151:175–89. PubMed DOI
Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120:2807–16. PubMed DOI
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021;325:843–54. PubMed DOI PMC
Locatelli F, Zugmaier G, Rizzari C, Morris JD, Gruhn B, Klingebiel T, et al. Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. Leukemia. 2023;37:222–5. PubMed DOI PMC
Charité–University Hospital of Berlin. International study for treatment of standard risk childhood relapsed ALL 2010. Available at: https://clinicaltrials.gov/ct2/show/NCT03590171. Accessed 31 March 2025.
Locatelli F, Eckert C, Hrusak O, Buldini B, Sartor M, Zugmaier G, et al. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022;69:e29715. PubMed DOI
Schrappe M, Locatelli F, Valsecchi MG, Cario G, Vossen-Gajcy M, Stary J, et al. Pediatric patients with high-risk B-cell ALL in first complete remission may benefit from less toxic immunotherapy with blinatumomab - Results from randomized controlled phase 3 trial AIEOP-BFM ALL 2017. Blood. 2023;142:825. DOI
Duffy C, Dang E, Yinmei Z, Bell J, Bhakta N, Henry M, et al. Safety and feasibility of blinatumomab as frontline therapy for pediatric patients with B-acute lymphoblastic leukemia and lymphoma: St. Jude Total Therapy Study XVII. ASH. 2024;4208. https://ash.confex.com/ash/2024/webprogram/Paper209284.html (last accessed on December 10, 2024).
An open-label randomized comparative trial of blinatumomab for B-cell acute lymphoblastic leukemia. JPRN. 2024. https://jrct.niph.go.jp/latest-detail/jRCT2031230581 (last accessed on December 10, 2024).
Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, et al. Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children. N Engl J Med. 2025;392:875–91. PubMed DOI PMC
